Exosomes Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana B

Exosomes Pipeline constitutes 80+ key companies continuously working towards developing 100+ Exosomes treatment therapies, analyzes DelveInsight.

Exosomes Overview:

Exosomes are small extracellular vesicles (30-150 nm) enclosed by a phospholipid bilayer, released by both eukaryotic and prokaryotic cells to facilitate intercellular communication and signaling. Initially thought to be vehicles for disposing of unwanted cellular waste, exosomes are now recognized as crucial molecular mediators that transport proteins, metabolites, and various nucleic acids throughout the body.

Exosomes play a role in immune responses, viral infections, pregnancy, cardiovascular and central nervous system-related diseases, as well as cancer progression. By delivering proteins, metabolites, and nucleic acids to recipient cells, exosomes can influence biological responses, either promoting or inhibiting disease processes. Their ability to regulate complex intracellular pathways has opened up opportunities for their therapeutic application, including in neurodegenerative diseases and cancer. Exosomes can be engineered to carry diverse therapeutic agents such as short interfering RNAs, antisense oligonucleotides, chemotherapeutic drugs, and immune modulators, with the added advantage of targeted delivery to specific sites.

Therapeutically, exosomes have several applications: they serve as biomarkers for disease diagnosis and monitoring, drug delivery vehicles, therapeutic agents, and immunomodulators that can either stimulate or suppress the immune system. Exosomes facilitate intercellular communication through various active biomolecules, including lipids, cytokines, growth factors, metabolites, proteins, and RNAs, during both normal and pathological processes. Their ability to influence cellular communication and intracellular pathways has significantly advanced their potential in managing and treating various diseases.

Request for a detailed insights report on Exosomes pipeline insights @ https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Exosomes Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Exosomes Therapeutics Market.

Key Takeaways from the Exosomes Pipeline Report

DelveInsight's Exosomes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment.
In January 2025, NurExone Biologic announced the acquisition of a master cell bank from a U.S. manufacturer, marking a significant step toward ensuring a stable and scalable supply chain for producing exosome-based therapies to meet clinical and patient treatment needs.
In July 2024, Aruna Bio secured a U.S. patent for the composition of matter for neural exosomes designed to deliver therapeutics to the brain.
That same month, ILIAS Biologics received the final clinical study report (CSR) for ILB-202 following a Phase I clinical trial completed in Australia in November 2023.
In April 2024:
- Biological Dynamics joined the growing number of customers utilizing the ExoVerita Pro instrument, an automated and cost-efficient exosomal enrichment platform.
- EXO Biologics raised up to EUR 16 million in Series A funding to advance exosome therapeutic development and clinical supply.
- ExoXpert entered a strategic partnership with Neucore Bio to leverage ExoXpert's platform for evaluating advanced exosome loading techniques.
- INOVIQ and Promega signed a global supply and distribution agreement for EXO-NET, following a co-marketing agreement established the previous year.
In March 2024, VivaZome Therapeutics and La Trobe University initiated a collaboration to investigate the therapeutic potential of extracellular vesicles in stroke models, led by Professor Chris Sobey.
Key Exosomes companies such asMiltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others are evaluating new drugs for Exosomes to improve the treatment landscape.
Promising Exosomes pipeline therapies in various stages of development include Brentuximab vedotin, Abexinostat, RNK05047, BMF-219, ADI-001, THOR-707, and others.

Exosomes Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Exosomes Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Exosomes market.

Download our free sample page report on Exosomes pipeline insights @ https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Exosomes Emerging Drugs

CAP-1002: Capricor Therapeutics
EXO-CD24: Nano24
AGLE-102: Aegle Therapeutics
Progenza: Cambium Bio
EV-101: EV Therapeutics

Exosomes Companies

More than 80 key companies are currently developing therapies involving exosomes. Among them, Capricor Therapeutics has drug candidates in the most advanced stage of development, specifically Phase III.

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Exosomes Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Exosomes Therapies and Key Companies: Exosomes Clinical Trials and advancements @ https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Exosomes Pipeline Therapeutic Assessment
• Exosomes Assessment by Product Type
• Exosomes By Stage
• Exosomes Assessment by Route of Administration
• Exosomes Assessment by Molecule Type

Download Exosomes Sample report to know in detail about the Exosomes treatment market @ Exosomes Therapeutic Assessment @ https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Exosomes Current Treatment Patterns
4. Exosomes - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Exosomes Late-Stage Products (Phase-III)
7. Exosomes Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Exosomes Discontinued Products
13. Exosomes Product Profiles
14. Exosomes Key Companies
15. Exosomes Key Products
16. Dormant and Discontinued Products
17. Exosomes Unmet Needs
18. Exosomes Future Perspectives
19. Exosomes Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Exosomes Pipeline Reports Offerings: https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.